Means, Motive, and Opportunity: SDH Mutations Are Suspects in Pituitary Tumors.BECKERS, Albert ![]() in Journal of Clinical Endocrinology and Metabolism (2013), 98(6), 2274-6 Detailed reference viewed: 5 (5 ULg) Characteristics of patients with pituitary gigantism : results of an international study; Daly, Adrian ; et alin Endocrine abstracts - 15th European Congress of Endocrinology (2013, May) Detailed reference viewed: 10 (3 ULg) Lessons from the Liege Acromegaly Survey (LAS)PETROSSIANS, Patrick ; ; et alin Endocrine Abstracts - 15 the European Congress of Endocrinology (2013, May) Detailed reference viewed: 10 (2 ULg) Receptor expression in craniopharyngiomas causing tumor growth in pregnancy : case report and review of the literature; VROONEN, Laurent ; THIRY, Albert et alin Endocrine Abstracts - 15th European Congress of Endocrinology (2013, May) Detailed reference viewed: 12 (2 ULg) A national survey on the prevalence and treatment outcome of active Cushing's disease in Belgium; ; et al in Endocrine Abstracts - 15th European Congress of Endocrinology (2013, May) Detailed reference viewed: 9 (1 ULg) Adenomas Pituitarios Familiares Aislados (FIPA)Beckers, Albert ![]() Scientific conference (2013, April) Detailed reference viewed: 12 (0 ULg) Historia de la Acromegalia y del GigantismoBeckers, Albert ![]() Scientific conference (2013, April) Detailed reference viewed: 20 (1 ULg) Epidemiology and genetics of pituitary tumorsBeckers, Albert ![]() Scientific conference (2013, February) Detailed reference viewed: 14 (1 ULg) Les adénomes hypophysaires : du diagnostic au traitement en passant par la contraception, la grossesse et la ménopauseBeckers, Albert ![]() Scientific conference (2013, January) Detailed reference viewed: 20 (4 ULg) 2013 European Thyroid Association guidelines for the diagnosis and treatment of TSH-secreting pituitary tumors; ; Beckers, Albert et alin European Thyroïd Journal (2013) Detailed reference viewed: 15 (3 ULg) Higher risk of death among MEN1 patients with mutations in the JunD interacting domain. A Groupe d'étude des Tumeurs Endocrines (GTE) cohort study; ; et al in Human Molecular Genetics (2013) BackgroundMultiple Endocrine Neoplasia syndrome type 1 (MEN1), which is secondary to mutation of the MEN1 gene, is a rare autosomal-dominant disease that predisposes mutation carriers to endocrine tumors ... [more ▼] BackgroundMultiple Endocrine Neoplasia syndrome type 1 (MEN1), which is secondary to mutation of the MEN1 gene, is a rare autosomal-dominant disease that predisposes mutation carriers to endocrine tumors. Although genotype-phenotype studies have so far failed to identify any statistical correlations, some families harbor recurrent tumor patterns. The function of MENIN is unclear but has been described through the discovery of its interacting partners. Mutations in the interacting domains of MENIN functional partners have been shown to directly alter its regulation abilities.MethodsWe report on a cohort of MEN1 patients from the Groupe d'etude des Tumeurs Endocrines. Patients with a molecular diagnosis and a clinical follow-up, totalling 262 families and 806 patients were included. Associations between mutation type, location or interacting factors of the MENIN protein and death as well as the occurrence of MEN1-related tumors were tested using a frailty Cox model to adjust for potential heterogeneity across families.ResultsAccounting for the heterogeneity across families, the overall risk of death was significantly higher when mutations affected the JunD interacting domain (adjusted HR=1.88: 95%-CI=1.15- 3.07). Patients had a higher risk of death from cancers of the MEN1 spectrum (HR=2.34; 95%-CI=1.23- 4.43).ConclusionThis genotype-phenotype correlation study confirmed the lack of direct genotype-phenotype correlations. However, patients with mutations affecting the JunD interacting domain had a higher risk of death secondary to a MEN1 tumor and should thus be considered for surgical indications, genetic counseling and follow-up. [less ▲] Detailed reference viewed: 19 (9 ULg) Familial Pituitary Adenomas : An overview; Daly, Adrian ; Beckers, Albert ![]() in Hayat, MA (Ed.) Tumors of the Central nervous system (2013) Detailed reference viewed: 30 (11 ULg) The Role of Aryl Hydrocarbon Receptor (AHR) and AHR-Interacting Protein (AIP) in the Pathogenesis of Pituitary Adenomas; Beckers, Albert ![]() in Hayat, MA (Ed.) Tumors of the Central nervous system (2013) Detailed reference viewed: 16 (8 ULg) Genetic analysis in young patients with sporadic pituitary macroadenomas:Beside AIP don't forget MEN1 genetic analysis.; ; et al in European Journal of Endocrinology (2013) CONTEXT: germline mutations in the AIP gene have been identified in young patients (age </= 30 years old) with sporadic pituitary macroadenomas. Otherwise, there are few data concerning the prevalence of ... [more ▼] CONTEXT: germline mutations in the AIP gene have been identified in young patients (age </= 30 years old) with sporadic pituitary macroadenomas. Otherwise, there are few data concerning the prevalence of MEN1 mutations in such population. OBJECTIVE: We assessed the prevalence of both AIP and MEN1 genetic abnormalities (mutations and large gene deletions) in young patients (age </= 30 years old) diagnosed with sporadic and isolated macroadenoma, without hypercalcemia and/or MEN1-associated lesions. DESIGN: The entire coding sequences of AIP and MEN1 were screened for mutations. In cases of negative sequencing screening, multiplex ligation-dependent probe amplification was performed for the detection of large genetic deletions. PATIENTS AND SETTINGS: 174 patients from Endocrinology Departments of 15 French University Hospital Centers were eligible for this study. RESULTS: 21/174(12%) patients had AIP (n=15, 8.6%) or MEN1 (n=6, 3.4%) mutations. In pediatric patients (age </= 18 years old), AIP/MEN1 mutation frequency reached nearly 22% (n=10/46). AIPmut and MEN1mut were respectively identified in 8/79 (10.1%) and 1/79 (1.2%) somatotropinoma patients; they each accounted for 4/74 (5.4%) prolactinoma patients with mutations. Half of patients (n=3/6) with gigantism displayed mutations in AIP. Interestingly, 4/12 (33%) patients with non-secreting adenomas bore either AIP or MEN1 mutations, whereas none of the 8 corticotroph-adenomas and a single thyrotropinoma case had mutations. No large gene deletions were observed in sequencing-negative patients. CONCLUSION: mutations in MEN1 can be of significance in young patients with sporadic isolated pituitary macroadenomas, particularly prolactinomas, and together with AIP, we suggest genetic analysis of MEN1 in such population. [less ▲] Detailed reference viewed: 17 (1 ULg) A prospective study of cardiac valvular status in patients treated with cabergoline for endocrine diseaseVROONEN, Laurent ; LANCELLOTTI, Patrizio ; et alin Symposium "Perspectives in Endocrinology" - Congresses Highlights 2012: ECE Firenze, ENDO Houston, ESPE Leipzig, SFE Toulouse, IWMEN Liège (2013) Detailed reference viewed: 18 (3 ULg) The role of tyrosin kinase inhibitors in a MEN2B patient with metastatic medullary thyroid carcinoma; ; VROONEN, Laurent et alin Symposium "Perspectives in Endocrinology" - Congresses Highlights 2012: ECE Firenze, ENDO Houston, ESPE Leipzig, SFE Toulouse, IWMEN Liège (2013) Detailed reference viewed: 18 (2 ULg) The clinical and genetic characteristics of patients with gigantism; ; et al in Symposium "Perspectives in Endocrinology" - Congresses Highlights 2012: ECE Firenze, ENDO Houston, ESPE Leipzig, SFE Toulouse, IWMEN Liège (2013) Detailed reference viewed: 15 (2 ULg) The clinical characteristics of pituitary adenomas (PA) in patients with primary hyperparathyroidism (PHPT) with and without MEN1 mutation; ; VALDES SOCIN, Hernan Gonzalo et alin Symposium "Perspectives in Endocrinology" - Congresses Highlights 2012: ECE Firenze, ENDO Houston, ESPE Leipzig, SFE Toulouse, IWMEN Liège (2013) Detailed reference viewed: 2 (2 ULg) Malabsorption des hormones thyroïdiennes... ou simple manque de compliance ?Benoit, Arnaud ; BOUQUEGNEAU, Antoine ; PETROSSIANS, Patrick et alin Revue Médicale de Liège (2013), 68(3), 118-121 Detailed reference viewed: 3 (0 ULg) Familial Isolated Pituitary Adenomas (FIPA) and the Pituitary Adenoma Predisposition due to Mutations in the Aryl Hydrocarbon Receptor Interacting Protein (AIP) Gene.BECKERS, Albert ; ; Daly, Adrian et alin Endocrine Reviews (2013) Pituitary adenomas are one of the most frequent intracranial tumors and occur with a prevalence of approximately 1:1000 in the developed world. Pituitary adenomas have a serious disease burden, and their ... [more ▼] Pituitary adenomas are one of the most frequent intracranial tumors and occur with a prevalence of approximately 1:1000 in the developed world. Pituitary adenomas have a serious disease burden, and their management involves neurosurgery, biological therapies, and radiotherapy. Early diagnosis of pituitary tumors while they are smaller may help increase cure rates. Few genetic predictors of pituitary adenoma development exist. Recent years have seen two separate, complimentary advances in inherited pituitary tumor research. The clinical condition of familial isolated pituitary adenomas (FIPA) has been described, which encompasses the familial occurrence of isolated pituitary adenomas outside of the setting of syndromic conditions like multiple endocrine neoplasia type 1 and Carney complex. FIPA families comprise approximately 2% of pituitary adenomas and represent a clinical entity with homogeneous or heterogeneous pituitary adenoma types occurring within the same kindred. The aryl hydrocarbon receptor interacting protein (AIP) gene has been identified as causing a pituitary adenoma predisposition of variable penetrance that accounts for 20% of FIPA families. Germline AIP mutations have been shown to associate with the occurrence of large pituitary adenomas that occur at a young age, predominantly in children/adolescents and young adults. AIP mutations are usually associated with somatotropinomas, but prolactinomas, nonfunctioning pituitary adenomas, Cushing disease, and other infrequent clinical adenoma types can also occur. Gigantism is a particular feature of AIP mutations and occurs in more than one third of affected somatotropinoma patients. Study of pituitary adenoma patients with AIP mutations has demonstrated that these cases raise clinical challenges to successful treatment. Extensive research on the biology of AIP and new advances in mouse Aip knockout models demonstrate multiple pathways by which AIP may contribute to tumorigenesis. This review assesses the current clinical and therapeutic characteristics of more than 200 FIPA families and addresses research findings among AIP mutation-bearing patients in different populations with pituitary adenomas. [less ▲] Detailed reference viewed: 21 (9 ULg) |
||